These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 8240704

  • 1. Clinical significance of the estrogen regulated pS2 protein in mammary tumors.
    Pichon MF, Milgrom E.
    Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704
    [Abstract] [Full Text] [Related]

  • 2. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A, Argibay S, Arias JI, Ruibal A.
    Rev Esp Med Nucl; 2005 Aug; 24(3):185-90. PubMed ID: 15847785
    [Abstract] [Full Text] [Related]

  • 3. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O, Bruscagnin G.
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
    Tamargo F, Vizoso F, Lamelas ML, Rodil A, Vérez P, Raigoso P, Mulero M, Vázquez J, Roiz C, Allende MT.
    Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
    [Abstract] [Full Text] [Related]

  • 5. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett M.
    Cancer Res; 1995 Jan 15; 55(2):288-93. PubMed ID: 7812959
    [Abstract] [Full Text] [Related]

  • 6. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I, Quénel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L.
    Br J Cancer; 1996 Oct 15; 74(7):1120-5. PubMed ID: 8855985
    [Abstract] [Full Text] [Related]

  • 7. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD.
    Cancer Res; 1991 Jan 15; 51(2):624-8. PubMed ID: 1985778
    [Abstract] [Full Text] [Related]

  • 8. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer.
    Rio MC, Chambon P.
    Cancer Cells; 1990 Jan 15; 2(8-9):269-74. PubMed ID: 2223388
    [Abstract] [Full Text] [Related]

  • 9. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells.
    Stack G, Kumar V, Green S, Ponglikitmongkol M, Berry M, Rio MC, Nunez AM, Roberts M, Koehl C, Bellocq P.
    Cancer Treat Res; 1988 Jan 15; 40():185-206. PubMed ID: 2908650
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
    Detre S, King N, Salter J, MacLennan K, McKinna JA, Dowsett M.
    J Clin Pathol; 1994 Mar 15; 47(3):240-4. PubMed ID: 8163696
    [Abstract] [Full Text] [Related]

  • 11. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJ, Neoptolemos JP.
    Eur J Cancer; 1994 Mar 15; 30A(1):5-11. PubMed ID: 8142164
    [Abstract] [Full Text] [Related]

  • 12. Expression of pS2 protein in breast cancer.
    Crombach G, Ingenhorst A, Göhring UJ, Scharl A, Neuhaus W, Möbus V, Schaeffer HJ.
    Arch Gynecol Obstet; 1993 Mar 15; 253(4):183-92. PubMed ID: 8161252
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
    Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M.
    Cancer Res; 1995 Aug 01; 55(15):3331-8. PubMed ID: 7614468
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
    Racca S, Conti G, Pietribiasi F, Stramignoni D, Tampellini M, Valetto MR, Ghezzo F, Di Carlo F.
    Int J Biol Markers; 1995 Aug 01; 10(2):87-93. PubMed ID: 7561244
    [Abstract] [Full Text] [Related]

  • 18. High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer.
    Yamakawa T, Morimoto T, Sasa M, Numoto S, Monden Y.
    Jpn J Cancer Res; 1995 Nov 01; 86(11):1035-40. PubMed ID: 8567393
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA, Rio MC, Seguin P, van Putten WL, Fauque J, Nap M, Klijn JG, Chambon P.
    Cancer Res; 1990 Jul 01; 50(13):3832-7. PubMed ID: 2354435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.